The acquisition will give Novartis full rights to CALY-002, Calypso’s lead product candidate.
Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - stock.adobe.com
On Jan. 8, 2024, Calypso Biotech, a European immunotherapy biotech company focused on the research and development of novel biologics, announced it had agreed to be acquired by Novartis. Calypso’s shareholders are set to receive an upfront payment of $250 million and are eligible to receive development milestones of up to $175 million, based on reaching certain milestones.
Calypso, a spin-out from Merck, is engaged in the research and development of monoclonal antibodies for a range of autoimmune indications, with a specialization in IL-15 biology. IL-15, according to Calypso, is a broad, untapped immune axis that controls barrier function and downstream immune cascades in many chronic autoimmune diseases. Calypso’s lead product candidate. CALY-002 is a potential best-in-class therapeutics antibody that binds to and neutralizes Interleukin-15.
This acquisition will give Novartis full rights to CALY-002, which it intends to explore further across a wide range of autoimmune indications with unmet medical need. CALY-002 is currently in a Phase Ib trial in patients with celiac disease and eosinophilic esophagitis.
“We are excited for this transaction with Novartis, a company with relentless commitment to the development of innovative therapies for autoimmune conditions. As part of the Novartis portfolio, CALY-002 is in the best position to be developed effectively, so that it can promptly address unmet medical needs in multiple indications,” said Alain Vicari, chief executive officer and co-founder of Calypso.
Bernard Coulie, chairman, Calypso, added, “The transaction with Novartis constitutes the high point in the development path of CALY-002 for the Calypso team. Calypso has established a significantly de-risked profile for CALY-002 as a potential best-in-class therapeutic anti-IL-15 antibody.”
“Novartis is committed to bringing innovative treatment options forward for patients living with immunological diseases,” said Richard Siegel, head of Immunology Research at Novartis in a Calypso press release. “We’re thrilled to add Calypso’s potential best-in-class antibody to our Immunology pipeline and explore it in a spectrum of autoimmune indications.”
Source: Calypso Biotech
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.